



IBA Dosimetry and Sun Nuclear Corporation settle on patent dispute

Schwarzenbruck, Germany, June 04th, 2014 – Sun Nuclear Corporation and IBA (Ion Beam Applications) Dosimetry GmbH are pleased to announce that they have resolved and settled all claims of the pending lawsuit (U.S. Patent No. 6,125,335, Case No. 6:13-cv-0968-Orl-31GJK, United States District Court for the Middle District of Florida).

As a result of the settlement, IBA Dosimetry GmbH, its parent Ion Beam Applications S.A., their subsidiaries and affiliates, as well as their customers, will not be affected in any way, now or in the future, by the patent dispute and/or its settlement outcome and can continue to use the technology associated with the patent without interruption or future risk.

Both parties have agreed not to disclose further details.

-ENDS-

About IBA

IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company. IBA is the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today. The Company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centres as well as next generation compact, single room systems.

IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety, as well as particle accelerators for medical and industrial applications.

Headquartered in Belgium and employing more than 1,000 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors by providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

Contact:

Rob Plompen
President IBA Dosimetry